Showing 1,361 - 1,380 results of 2,945 for search '"hepatitis"', query time: 0.08s Refine Results
  1. 1361
  2. 1362
  3. 1363
  4. 1364
  5. 1365
  6. 1366
  7. 1367
  8. 1368
  9. 1369
  10. 1370
  11. 1371
  12. 1372
  13. 1373
  14. 1374
  15. 1375
  16. 1376
  17. 1377
  18. 1378
  19. 1379

    Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada) by Robert P Myers, Curtis Cooper, Morris Sherman, Richard Lalonde, Helga Witt-Sullivan, Magdy Elkashab, Paul Harris, Rob Balshaw, Christopher Usaty, Paul J Marotta

    Published 2011-01-01
    “…BACKGROUND: In patients chronically infected with the hepatitis C virus (HCV), it is not established whether viral outcomes or health-related quality of life (HRQoL) differ between individuals treated at academic or community centres.…”
    Get full text
    Article
  20. 1380

    15-Deoxy-γ12,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPARγ and Reduction in NF-κB Activity by Kan Chen, Jingjing Li, Junshan Wang, Yujing Xia, Weiqi Dai, Fan Wang, Miao Shen, Ping Cheng, Yan Zhang, Chengfen Wang, Jing Yang, Rong Zhu, Huawei Zhang, Yuanyuan Zheng, Jie Lu, Zhuoyi Fan, Yingqun Zhou, Chuanyong Guo

    Published 2014-01-01
    “…In this study, we investigated both effects of 15d-PGJ2 and its protection mechanism in concanavalin A- (ConA-) induced autoimmune hepatitis in mice. Materials and Methods. In vivo, Balb/C mice were injected with ConA (25 mg/kg) to induce acute autoimmune hepatitis, and 15d-PGJ2 (10 μg or 25 μg) was administered 1 h before the ConA injection. …”
    Get full text
    Article